Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Clinical Programs
    • IRAK1/4
    • RIPK1
    • Partnered Programs
    • Clinical Trials
    • Investigator Sponsored Research
    • Expanded Access Policy
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • ESG
  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts
  • All Years
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • All Releases
  • Financial Releases
Mar 08, 2016 4:05pm EST

Rigel Announces Fourth Quarter and Year End 2015 Financial Results

Mar 08, 2016 4:03pm EST

Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer

Mar 01, 2016 7:30am EST

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2015 Financial Results

Feb 29, 2016 7:30am EST

Rigel to Present at Cowen and Company 36th Annual Health Care Conference

Feb 25, 2016 7:30am EST

Rigel Initiates Phase 2 Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia

Jan 28, 2016 7:30am EST

Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP (FIT)

Jan 07, 2016 7:30am EST

Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco

Nov 03, 2015 4:05pm EST

Rigel Announces Third Quarter 2015 Financial Results

Oct 27, 2015 7:30am EDT

Rigel Announces Conference Call and Webcast to Report Third Quarter 2015 Financial Results

Sep 09, 2015 8:30am EDT

Rigel and Aclaris Therapeutics International Sign License Agreement for JAK Inhibitors to Treat Skin Disorders

  • Previous
  • 1…
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • …41
  • Next
RSS
  • Email Alerts
  • RSS News Feed
Terms of Use Privacy Policy Your Cookie Preferences

© 2025 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, REZLIDHIA, GAVRETO, RIGEL and the Rigel arc logo are registered trademarks of Rigel Pharmaceuticals, Inc.

Facebook Twitter Linkedin